CVI
Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Munson, E. L.
Right arrow Articles by Schell, R. F.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Munson, E. L.
Right arrow Articles by Schell, R. F.

 Previous Article  |  Next Article 

Clinical and Vaccine Immunology, January 2006, p. 19-25, Vol. 13, No. 1
1071-412X/06/$08.00+0     doi:10.1128/CVI.13.1.19-25.2006
Copyright © 2006, American Society for Microbiology. All Rights Reserved.

Interleukin-6 Promotes Anti-OspA Borreliacidal Antibody Production In Vitro

Erik L. Munson,1,4,{dagger} Dean T. Nardelli,1,2 K. H. Kevin Luk,1,3 Monica C. Remington,1,4 Steven M. Callister,5 and Ronald F. Schell1,2,3,4*

Wisconsin State Laboratory of Hygiene,1 Departments of Comparative Biomedical Sciences,2 Bacteriology,3 Medical Microbiology and Immunology, University of Wisconsin, Madison, Wisconsin 53706,4 Microbiology Research Laboratory and Department of Infectious Diseases, Gundersen Lutheran Medical Center, La Crosse, Wisconsin 546015

Received 11 July 2005/ Returned for modification 7 September 2005/ Accepted 21 September 2005

Determination of the immunological mediators responsible for promoting the production of borreliacidal antibody may facilitate the development of an improved borreliosis vaccine for human and veterinary use. Previously, we developed an in vitro assay to determine if borreliacidal antibody production could be augmented by treatment with different cytokines. In this study, in vitro treatment of lymph node cells producing borreliacidal antibody with recombinant interleukin-6 (rIL-6) resulted in a fourfold enhancement of anti-OspA borreliacidal antibody. Moreover, rIL-6 enhanced Western immunoblot titers and increased the number of B lymphocytes. In contrast, treatment of anti-OspA borreliacidal antibody-producing cells with anti-IL-6 resulted in a fourfold reduction in borreliacidal activity. Treatment with anti-IL-6 also inhibited enhanced borreliacidal antibody production induced by anti-gamma interferon. These data suggest that IL-6 plays a significant role in the production of anti-OspA borreliacidal antibodies.

* Corresponding author. Mailing address: University of Wisconsin, Wisconsin State Laboratory of Hygiene, 465 Henry Mall, Madison, WI 53706. Phone: (608) 262-3634. Fax: (608) 265-3451. E-mail: RFSchell{at}wisc.edu.

{dagger} Present address: Medical Science Laboratories, 11020 West Plank Court, Wauwatosa, WI 53226.

Clinical and Vaccine Immunology, January 2006, p. 19-25, Vol. 13, No. 1
1071-412X/06/$08.00+0     doi:10.1128/CVI.13.1.19-25.2006
Copyright © 2006, American Society for Microbiology. All Rights Reserved.





Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
Antimicrob. Agents Chemother. Clin. Microbiol. Rev. Infect. Immun.
J. Clin. Microbiol. J. Virol. ALL ASM JOURNALS

Copyright © 2006 by the American Society for Microbiology. All rights reserved.